or its pharmaceutically acceptable salt, preferably pharmaceutically acceptable acid additive salt, more preferably monomethanesulfonate salt for preparing pharmaceutical compositions used in treatment of proliferative arthritis, in particular, a severe form of proliferative arthritis and DMARD-resistant proliferative arthritis. Method for treatment of treatment of patients suffering from proliferative arthritis involves administration in a patient needing such treatment of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]benzamide of the formula (I) or its pharmaceutically acceptable salt, in particular, in form of monomethanesulfonate salt in the effective dose against proliferative arthritis, and monomethanesulfonate salt of compound of the formula (I) is administrated in a daily dose corresponding to from 100 to 1000 mg of compound of the formula (I) in form of free base, and administration is carried out once per a day for period above 3 months. Also, invention relates to a combination used in treatment of proliferative arthritis comprising (a) 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]benzamide of the formula (I) or its pharmaceutically acceptable salt, and (b) the second drug chosen from prednison, ciclosporin and hydroxychloroquine.;EFFECT: valuable medicinal properties of compound, enhanced effectiveness of treatment.;12 cl, 1 tbl, 3 ex"/>
TREATMENT OF PROLIFERATIVE ARTHRITIS
FIELD: organic chemistry, medicine, pharmacology.;SUBSTANCE: invention proposes using 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]benzamide of the formula (I): or its pharmaceutically acceptable salt, preferably pharmaceutically acceptable acid additive salt, more preferably monomethanesulfonate salt for preparing pharmaceutical compositions used in treatment of proliferative arthritis, in particular, a severe form of proliferative arthritis and DMARD-resistant proliferative arthritis. Method for treatment of treatment of patients suffering from proliferative arthritis involves administration in a patient needing such treatment of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]benzamide of the formula (I) or its pharmaceutically acceptable salt, in particular, in form of monomethanesulfonate salt in the effective dose against proliferative arthritis, and monomethanesulfonate salt of compound of the formula (I) is administrated in a daily dose corresponding to from 100 to 1000 mg of compound of the formula (I) in form of free base, and administration is carried out once per a day for period above 3 months. Also, invention relates to a combination used in treatment of proliferative arthritis comprising (a) 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]benzamide of the formula (I) or its pharmaceutically acceptable salt, and (b) the second drug chosen from prednison, ciclosporin and hydroxychloroquine.;EFFECT: valuable medicinal properties of compound, enhanced effectiveness of treatment.;12 cl, 1 tbl, 3 ex
展开▼
